COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
for Diabetic Macular Edema
50 locations incl. Bakersfield
Sponsor: EyePoint Pharmaceuticals, Inc.
Sex: All·Age: 18+
Code: NCT07449936·Phase 3·Recruiting·Listed Mar 2026